Research

 

Overview

Center for Research Translation (CORT) Grant

Psoriasis Presentations

Psoriasis Publications

Psoriasis Database Study Participants

 

Overview

There are 7.5 million psoriasis patients in the United States. Fifty-eight percent of those with psoriasis experience inadequate treatment because current major therapies are sometimes ineffective, unavailable, or unsatisfactory. Current major therapies often help psoriasis, but can increase skin aging, skin cancer, liver or kidney toxicity, blood lipids, or blood pressure. We are committed to helping develop improved therapeutic approaches without the above drawbacks.

Our Dermatology faculty have established a full spectrum of projects which will benefit patients who suffer from psoriasis. Our highly experienced staff takes great pride in providing top quality, well-established therapies with proven efficacy. We work hard to obtain advanced treatments that we believe are safe but have a strong chance of benefit. Thus we can provide early access for our patients to newly developing therapies that are not yet generally available. We are also one of a few centers worldwide with psoriasis awards from the National Institutes of Health, the Dermatology Foundation, and the Department of Veterans Affairs to research how psoriasis lesions are caused, and to develop entirely new ways of treating psoriasis without the side effects of our current therapies.

The Murdough Family Center for Psoriasis, newly created by a generous gift from the Murdough Foundation, will allow us to bring benefit to more patients with the disease. The Murdough Family Center for Psoriasis incorporates both the psoriasis research and treatment efforts of the medical center, and creates new community interfaces and a complete approach to both the mind and the body aspects of psoriasis.

 

Center for Research Translation (CORT)

The National Institute of Health (NIH) recently awarded Case Western Reserve University and University Hospitals Case Medical Center a $6.3 millon award to establish a Center of Research Translation (CORT) in Psoriasis. This is one of the largest grants ever given to a medical institution in the United States for the study of psoriasis.

Psoriasis CORT Overview

NIAMS Press Release

CASE Press Release

A Center of Research Translation (CORT) in Psoriasis based at University Hospitals Case Medical Center will integrate a strong psoriasis and skin disease research base with a large existing cohort of psoriasis patients. $5M from the new University Hospitals Murdough Family Center for Psoriasis will further increase the capabilities and geography of the clinical referral network, and in combination with $2M from Case School of Medicine for recruitment in psoriasis, these resources comprise a substantial institutional commitment to the CORT. The Skin Diseases Research Center’s cutaneous biology infrastructure and experience will accelerate the Case Psoriasis CORT’s advances for psoriasis patient benefit. The translational projects envisioned will test innovative therapeutic interventions in psoriasis that are based upon new mechanistic findings. They also provide new pathogenetic information using biologic samples from patients and animal models. It is intended that each Project will generate therapeutic modalities that change the treatment of psoriasis patients.

Project 1: Pc4 PDT for Psoriasis
PI: Elma Baron, MD
 
This is a novel photodynamic therapy (PDT) Phase I mechanistic, safety, and preliminary efficacy study which also develops a real-time patient-optimized therapy device.

Project 2:S100 A8/A9 and Macrophages in Psoriasis
PI: Kevin D. Cooper, MD 

This is a basic study that determines novel roles for S100 proteins in the pathogenesis of psoriasis, including proof-of-principle testing of S100 and macrophage interplay in psoriasis skin on xenogenic transplants.

Project 3: VEGF Influences Keratinocyte-Immunocyte Interactions in Psoriasiform Dermatitis
PI: Nicole Ward, PhD
This project takes advantage of a novel transgenic mouse model of psoriasiform dermatitis to examine the potential role of VEGF, S100 A8/9 and vascular changes exacerbating psoriasis.

 

Psoriasis Database Study Participants

Thank you for your interest in enrolling in our database. The purpose of the database is to gather comprehensive data on your personal and medical history, detailed history of your psoriasis, including the current and past treatments you have received, and medical history of your family members including psoriasis. Information gathered will be stored in an electronic database, which may help researchers develop a better understanding of this disease, and thus lead to future studies improving the management of psoriasis. If you have previously consented (in person or by phone) for the study entitled "Epidemiology, comorbidities, risk factors, and treatment profile of psoriasis patients (UH IRB # 03-07-31)," click here to start the online survey.

Back to top 

Psoriasis Presentations

2008

Should One of the Goals of Psoriasis Treatment be Controlling Cardiovascular Disease?
American Academy of Dermatology, San Antonio, TX
Neil J. Korman, MD PhD

A New Psoriasis Patient Management Concept That Includes Community Dermatologists, NP's, and Local Experts
American Academy of Dermatology, San Antonio, TX
Neil J. Korman, MD PhD

When and How To Use Scary Drugs
American Academy of Dermatology, San Antonio, TX
Neil J. Korman, MD PhD

Psoriasis Co-Morbidities. Is a New Paradigm Emerging?
Southwest Florida Dermatology Society, Tampa, FL 
Neil J. Korman, MD PhD

Psoriasis: A Risk Factor for Cardiovascular Disease?
American Academy of Dermatology, Chicago, IL
Neil J. Korman, MD PhD

Autoimmune Blistering Diseases and Psoriasis: A 21st Century Update
Charlotte Dermatology Society, Charlotte, NC 
Neil J. Korman, MD PhD

Anti-T Cell Agents for the Treatment of Psoriasis
National Psoriasis Foundation/American Academy of Dermatology Chief Residents Meeting, Chicago, IL
Neil J. Korman, MD PhD

Systemic Agents for the Treatment of Psoriasis
National Psoriasis Foundation/American Academy of Dermatology Chief Residents Meeting, Chicago, IL
Neil J. Korman, MD PhD

2007

Advances in the Treatment of Psoriasis With Biologic Therapies
Virginia Beach Dermatology Grand Rounds, Virginia Beach, VA
Neil J. Korman, MD PhD

Combination Immunosuppressive Therapies: The Promise and The Peril
American Academy of Dermatology, Washington DC
Neil J. Korman, MD PhD

How and When To Use Scary Drugs
American Academy of Dermatology, Washington DC
Neil J. Korman, MD PhD

2006

Alefacept: The Newest Developments
Hawaii Dermatology Seminar, Kauai, HI 
Neil J. Korman, MD PhD

Biologics for Psoriasis: A Mechanism of Action Based Approach
American Academy of Dermatology, San Francisco, CA
Neil J. Korman, MD PhD

2005

Biologics in Psoriasis: A Clinical and Laboratory Approach
American Academy of Dermatology, New Orleans, LA
Neil J. Korman, MD PhD

Investigating Selective T–Cell Targeting in Psoriasis: Optimizing Outcomes in Clinical Practice
Skin Disease Education Foundation, Maui, HI
Neil J. Korman, MD PhD

Update on Biological Therapies for the Treatment of Psoriasis
TriServices Military Dermatology Conference, Bethesda, MD
Neil J. Korman, MD PhD

Classical Immunomodulatory Therapies
American Academy of Dermatology Session. Chicago, IL
Neil J. Korman, MD PhD

Biologics in the Treatment of Psoriasis and Other Allied Conditions
TNF and Beyond: Treatment of Autoimmune and Inflammatory Disorders Summit, Cleveland, OH
Neil J. Korman, MD PhD

An Open Label Dose Escalation Study of Alefacept for Adults with Chronic Plaque Psoriasis
American Dermatologic Association, Greensboro, NC
Neil J. Korman, MD PhD

Advances in the Treatment of Psoriasis With Biologic Therapies
University of Minnesota, Minneapolis, MN
Neil J. Korman, MD PhD

Biologic Therapies for Psoriasis: Where Are We Today? 
University of Louisville, Louisville, KY

Neil J. Korman, MD PhD

2004

Biologics in Psoriasis: A Clinical and Laboratory Approach
American Academy of Dermatology, Washington, DC
Neil J. Korman, MD PhD

New Biologic Therapies in the Treatment of Psoriasis
Vanderbilt University, Nashville, TN
Neil J. Korman, MD PhD

What Every Dermatologist Needs to Know About the Treatment of Psoriasis
American Academy of Dermatology Symposium, Las Vegas, NV
Neil J. Korman, MD PhD

Efalizumab Treatment for Patients with Psoriasis: Real World Approach
Skin Disease Education Foundation, Phoenix, AR
Neil J. Korman, MD PhD

The Newest Biologic Therapies for the Treatment of Psoriasis
Univ of Connecticut, Farmington, CT
Neil J. Korman, MD PhD

Alefacept: New Developments
Psoriasis Course at American Academy of Dermatology, NY, NY
Neil J. Korman, MD PhD

21st Century Immunomodulatory Therapies
New Therapies Course at American Academy of Dermatology, NY, NY
Neil J. Korman, MD PhD

Systemic Therapies for the Treatment of Psoriasis
Skin Disease Education Foundation, Santa Fe, NM
Neil J. Korman, MD PhD

Alefacept: A Potentially Remittive Therapy for the Treatment of Psoriasis
Skin Disease Education Foundation, Santa Fe, NM
Neil J. Korman, MD PhD

Practical Considerations in the Treatment of Patients with Psoriasis
American Academy of Dermatology Symposium, Chicago, IL
Neil J. Korman, MD PhD

What Every Dermatologist Needs to Know About the Treatment of Psoriasis
American Academy of Dermatology Symposium, Chicago, IL
Neil J. Korman, MD PhD

Treatment of Psoriasis With an Emphasis on New Biologic Therapies
Piedmont Dermatology Society, Blowing Rock, NC
 
Neil J. Korman, MD PhD


Back to top

 

Psoriasis Publications

Johnston A, Xing X, Guzman AM, Riblett M, Loyd CM, Ward NL, Wohn C, Prens EP, Wang F, Maier LE, Kang S, Voorhees JJ, Elder JT, Gudjonsson JE. IL-1F5, -F6, -F8, and -F9: A Novel IL-1 Family Signaling System That Is Active in Psoriasis and Promotes Keratinocyte Antimicrobial Peptide Expression. J Immunol. 2011 Jan 17. [Epub ahead of print] PubMed PMID: 21242515.

Ostrowski, S.M., Belkadi, A., Loyd, C.M, Diaconu, D. and Ward, N.L. (2011). Cutaneous denervation of psoriasiform mouse skin improves acanthosis and inflammation in a substance P and CGRP dependent manner. J Invest Derm. In Press

Bata-Csorgo Z, Hammerberg C, Voorhees JJ, and Cooper KD. 1993. Flow cytometric identification of proliferative subpopulations within normal human epidermis and the localization of the primary hyperproliferative population in psoriasis. J Exp Med 178: 1271-81.

Bata-Csorgo Z, Hammerberg C, Voorhees JJ, and Cooper KD. 1995. Kinetics and regulation of human keratinocyte stem cell growth in short term primary ex vivo culture; growth factors cooperative with IFN gamma from psoriatic lesional T lymphocyte timulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes. J Clin Invest 95: 317-27.

Skov L, Chan LS, Fox DA, Larsen JK, Voorhees JJ, Cooper KD, and Baadsgaard O. 1997. Lesional psoriatic T cells contain the capacity to induce a T cell activation molecule CDW60 on normal keratinocytes. Am J Pathol 150: 675-83.

Szabo SK, Hammerberg C, Yoshida Y, Bata-Csorgo Z, and Cooper KD. 1998. Identification and quantitation of interferon-producing T cells in psoriatic lesions: Localization to both CD4+ and CD8+ subsets. J Invest Dermatol 111: 1072-8.

Bata-Csorgo Z, Cooper KD, Voorhees JJ, and Hammerberg C. 1998. Fibronectin and 5 integrin regulate keratinocyte stem cell recycling: A mechanism for increased fibronectin potentiation of T cell lymphokine-driven keratinocytic stem cell hyperproliferation in psoriasis. J Clin Invest 101:1509-18.

Ting KM, McCormick TS, Hammerberg C, Chen G, Gilliam AC, and Cooper KD. 2000. Overexpression of the oncofetal Fn variant containing the EDA splice-in segment in the dermal-epidermal junction of the psoriatic uninvolved skin. Journal of Investigative Dermatology 114:706-11.

McCormick TS, Stevens SR, and Kang K. 2000. Macrophages and cutaneous inflammation. Nature Biotechnology 18:25-6.

Chen G, McCormick TS, Hammerberg C, Ryder-Diggs S, Stevens SR, and Cooper KD. 2001. Basal keratinocytes from uninvolved psoriatic skin exhibit accelerated spreading and focal adhesion kinase (FAK) responsiveness to fibronectin. Journal of Investigative Dermatology 117:1538-1545.

Gordon KB and McCormick TS. 2003. Evolution of biologic therapies for the treatment of psoriasis. Skinmed 2(5):286-94.

Kauffman CL, Aria N, Toichi E, McCormick TS, Cooper KD, Gottlieb AB, Everitt DE, Fredereick B, Zhu Y, Graham MA, Pendley CE, and Mascelli MA. 2004. A phase I study evaluating the safety, pharmacokinetics, and clinical response of human IL-12 p40 antibody in subjects with plaque psoriasis. Journal of Investigative Dermatology 123(6): 1037-44.

Sugiyama H, Gyulai R, Toichi E, Garaczi E, Shimada S, Stevens SR, McCormick TS, and Cooper KD. 2005. Dysfunctional blood and target tissue CD4+ CD25high regulatory T cells in psoriasis: Mechanism underlying unrestrained pathogenic effector T cell proliferation. Journal of Immunology 174(1): 164-73.

Moul DK and Korman NJ. 2005. The Early Signs and Symptoms of Psoriatic Arthritis: The Importance of Early Evaluation and Treatment. Psoriasis Forum, 11:4-6.

Kagen M, McCormick T, and Cooper KD. 2006. Regulatory T cells in psoriasis. Ernst Schering Res Foundation Workshop. 56:193-209.

Toichi E, Torres G, McCormick TS, Chang T, Mascelli MA, Kaufmann CL, Aria N, Gottlieb AB, Everitt DE, Frederick B, Pendley CE, and Cooper KD. 2006. An anti-IL-12 p40 antibody downregulates type 1 cytokines, chemokines and IL-12/IL-23 in psoriasis. Journal of Immunology 177(7): 4917-26.

Korman NJ and Moul DK. 2005. Alefacept for the treatment of psoriasis. Sem Cut Med Surg 24: 10-8.

Voskas D, Jones N, Van Slyke P, Sturk C, Chang W, Haninec A, Babichev YO, Tran J, Master Z, Chen S, Ward N, Cruz M, Jones J, Kerbel RS, Jothy S, Dagnino L, Arbiser J, Klement G, and Dumon DJ. 2005. A cyclosporine-sensitive psoriasis-like disease produced in Tie2 transgenic mice. Am J of Pathology 166: 843-55.

Gordon K, Korman NJ, Frankel E, Wang H, Jahreis A, and Zitnik R. 2006. Efficacy of etanercept in an integrated database of patients with psoriasis. J Am Acad Dermatol 54: S101-6.

Routhouska SB and Korman NJ. 2006. Initiating and monitoring patients on biologic therapy for psoriasis beyond the FDA: Our more cautious approach. Psoriasis Forum 12: 12-5.

Pariser DM, Bagel J, Gelfand JM, Korman NJ, Richlin CT, et al. National Psoriasis Foundation clinical consensus on psoriasis disease severity. In Press, 2006.

Robinson MR and Korman NJ. The use of biologics in psoriasis patients with co-morbidities. In Press, 2006.

Moul DK, Routhouska SB, Korman NJ . Open-Label, Single-Center, Safety Dose Escalation Trial of Alefacept for the Treatment of Moderate to Severe Chronic Plaque Psoriasis.  J Cutan Med Surg 2007; 11:132-136.

Robinson MR, Korman BD, Korman NJ . Combination Immunosuppressive Therapies: The Promise and The Peril. Arch Dermatol, 2007; 143:1053-1058.

DM Pariser, J Bagel, JM Gelfand, NJ Korman , CT Ritchlin, BE Strober, AS Van Voorhees, M Young, S Rittenberg , M Lebwohl, EJ Horn. National Psoriasis Foundation Clinical Consensus on Psoriasis Disease Severity:  Arch Dermatol, 2007; 143:239-242.

Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Mark Lebwohl,   Koo JYM, Elmets CA, Korman NJ , Beutner KR, Bhushan R. Guidelines of Care for the Diagnosis and Management of Psoriasis and Psoriatic Arthritis: Overview of Psoriasis and Guidelines of Care for the Treatment of Psoriasis with Biologics. J Am Acad Dermatol; 2008; 58:826-850.

Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JYM, Van Voorhees AS, Elmets CA, Leonardi CL, Beutner KR, Bhushan R, Menter A. Guidelines of Care for the Diagnosis and Management of Psoriasis and Psoriatic Arthritis Psoriatic Arthritis: Overview and Guidelines of Care for Treatment with an Emphasis on the Biologics. J Am Acad Dermatol; 2008; 58:851-864.

Lebwohl M, Bagel J, Gelfand JM, Gladman D, Gordon KB, Hsu S, Kalb RE, Kimball AB, Korman NJ, Krueger GG, Mease P, Morison WL, Paller A, Pariser DM, Ritchlin C, Strober B, Van Voorhees A, Weinstein GD, Young M, Horn L. From the Medical Board of the National Psoriasis Foundation: Monitoring and Vaccinations in Patients Treated with Biologics for Psoriasis. J Am Acad Dermatol. 2008; 58:94-105 

Ward NL, Loyd CM, Wolfram JA, Diaconu D, Michaels CM, McCormick TS.
Depletion of antigen presenting cells by clodronate liposomes reverses the
psoriatic skin phenotype in KC-Tie2 mice. Br J Dermatol. 2010 Nov 11.
doi:10.1111/j.1365-2133.2010.10129.x. [Epub ahead of print] PubMed PMID:
21070202.

Ward NL, Hatala DA, Wolfram JA, Knutsen DA, Loyd CM. Cutaneous manipulation
of vascular growth factors leads to alterations in immunocytes, blood
vessels and nerves: Evidence for a cutaneous neurovascular unit. J Dermatol
Sci. 2011 Jan;61(1):14-22. Epub 2010 Nov 13. PubMed PMID: 21129919.

Johnston A, Xing X, Guzman AM, Riblett M, Loyd CM, Ward NL, Wohn C, Prens
EP,  Wang F, Maier LE, Kang S, Voorhees JJ, Elder JT, Gudjonsson JE. IL-1F5,
-F6, -F8, and -F9: A Novel IL-1 Family Signaling System That Is Active in
Psoriasis and Promotes Keratinocyte Antimicrobial Peptide Expression. J
Immunol. 2011 Jan 17. [Epub ahead of print] PubMed PMID: 21242515.

Ostrowski, S.M., Belkadi, A., Loyd, C.M, Diaconu, D. and Ward, N.L. (2011).
Cutaneous denervation of psoriasiform mouse skin improves acanthosis and
inflammation in a substance P and CGRP dependent manner. J Invest Derm. In

Press.